Fig. 1



Responses on pool
SFC/10^6 cells
800
600
400
200
0
CT26-5 INV
CT26-5 TPA
CT26-5

Fig. 2



GAd-CT26-5 TPA: IFN-γ ELISpot
GAd-CT26-31 TPA: IFN-γ ELISpot
SFC/10^6 splenocytes
1,200
1,000
800
600
400
200
30
15
0
NeoAg#
10
21
11
4
5
18
23
28
DMSO

Fig. 3



Day -15
GAd
Day 0
CT26 inoculum
TUMOR
MONITORING
100%
TF
100%
TF
0%
TF
Tumor volume (mm3)
2,000
1,500
1,000
500
0
GAd-CT26-5
GAd-CT26-31
mock

Fig. 4



CT26 iv
GAd
LUNG METASTASIS
Day0
Day3
Day16
#lung nodules
25
20
15
10
5
0
GAd-CT26-5
GAd-CT26-31
Cntr

Fig. 5 A



A)
Established tumor
CT26 inoculum
Day 0
GAd
TUMOR
MONITORING
GAd-CT26-31
Cntr
Tumor volume (mm3)
2000
1500
1000
500
400
200
0
d0 d3 d6 d10 d13 d17 d20 d24 d30

Fig. 5 B



B)
anti-PD1
GAd-CT26-5 & anti-PD1
GAd-CT26-31 & anti-PD1
Tumor volume (mm3)
15% CR
3/20
15% CR
3/20
48% CR
10/21
*p = 0.02
days
2000
1500
1000
500
400
200
d0 d3 d6 d10 d13 d17 d20 d24 d30

Fig. 6



GAd-CT26-31&anti-PD1
SFC/10^6 splenocytes
800
700
600
500
400
300
200
100
50
0
NeoAg ID
4
5
10
11
18
21
23
28

Fig. 7




GAd-CT26-31&anti-PD1
Undepleted
NS
CD4 depleted
*
CD8 depleted
Tumor volume (mm3)
2000
1500
1000
500
400
200
0
d0 d4 d7 d12 d14 d18 d20 d26
days

Fig. 8


p-value=0.001
Number of clonotypes
60
50
40
30
20
10
0
Combined treatment
anti-PD1